CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Palbociclib (Ibrance) — Coverage Criteria and Prior Authorization

Defines prior authorization, coverage indications, and continuation criteria for palbociclib (Ibrance) for Neighborhood Health Plan of Rhode Island members when prescribed for FDA-approved and compendial uses.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyPalbociclib (Ibrance) — Coverage Criteria and Prior Authorization

Policy CodePolicy N/A

Change TypeNone

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and submit HR and HER2 status; authorization up to 12 months may be granted for eligible indications.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

HR+, HER2-primary biomarker

Sarcomacompendial use

Coverage Criteria for Palbociclib (Ibrance)

inv-01: Covered indications

Covered when ALL of the following are met for the specified indication:

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Breast cancer indication: Patient has hormone receptor (HR)-positive, HER2-negative recurrent, advanced, or metastatic breast cancer and palbociclib (Ibrance) is prescribed in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or in combination with fulvestrant for disease progression following endocrine therapy.

Based on FDA-approved indications; authorization of up to 12 months may be granted.

Soft tissue sarcoma (compendial): Patient has unresectable well-differentiated or dedifferentiated liposarcoma of the retroperitoneum and palbociclib (Ibrance) is being used as single-agent therapy.

Compendial use; authorization of up to 12 months may be granted.

inv-02: Continuation therapy

Covered for continuation when ALL of the following are met:

Clinical benefit: There is no evidence of unacceptable toxicity or disease progression while on the current palbociclib regimen.

Authorization for continuation may be granted for 12 months; provider must document lack of progression/toxicity for renewal.

Initial Authorization Criteria

inv-11: Initial therapy authorization

Initial authorization: Authorization of 12 months may be granted for treatment of HR-positive, HER2-negative recurrent, advanced, or metastatic breast cancer when palbociclib (Ibrance) is used in combination with an aromatase inhibitor or in combination with fulvestrant.

Provider must specify the endocrine therapy combination (aromatase inhibitor or fulvestrant).

inv-12: Compendial initial therapy

Sarcoma initial authorization: Authorization of 12 months may be granted for treatment of unresectable well-differentiated or dedifferentiated liposarcoma of the retroperitoneum when palbociclib (Ibrance) is used as a single agent.

Compendial single-agent use.

Reauthorization / Continuation Rules

inv-13: Continuation authorization

Reauthorization rules

Reauthorization requirement: Continued treatment may be authorized for 12 months if there is no unacceptable toxicity or disease progression on the current regimen.

Provider must document lack of progression or unacceptable toxicity to support renewal.

Provider Requirements and Actionable Rules

Prior Authorization

Prior Authorization Required

Prior authorization is required for Ibrance (palbociclib). Authorization of up to 12 months may be granted for eligible indications such as HR-positive, HER2-negative advanced/metastatic breast cancer and compendial uses (e.g., unresectable well-differentiated/dedifferentiated retroperitoneal liposarcoma) when clinical criteria are met.

Authorization may be granted for up to 12 months for covered indications
Prior authorization required before treatment initiation

Step Therapy

Step-Therapy Notes

No explicit step-therapy sequence is required beyond combination-therapy specifics. Ensure combination therapy requirements are met (for example, use in combination with an aromatase inhibitor or fulvestrant for HR-positive, HER2-negative breast cancer).

Ibrance is indicated in combination with an aromatase inhibitor for initial endocrine-based therapy in postmenopausal women or in men
Ibrance is indicated in combination with fulvestrant for patients with disease progression following endocrine therapy

Documentation Required

Required Biomarker Documentation

Submit hormone receptor (HR) status and HER2 status as part of the prior authorization request when applicable. These biomarkers are required to verify the patient meets HR-positive, HER2-negative disease criteria for covered breast cancer indications.

Provide HR (estrogen and/or progesterone receptor) status
Provide HER2 testing results (IHC/FISH) where available

Denial Risk

Non-covered Indications

Use of Ibrance for indications outside the listed FDA-approved or compendial uses (including uses not described in this policy) is considered experimental/investigational and is not medically necessary; such uses will be denied.

Not medically necessary for indications other than HR-positive, HER2-negative advanced/metastatic breast cancer and listed compendial uses (e.g., retroperitoneal well-differentiated/dedifferentiated liposarcoma)
Requests for unlisted indications should include supporting evidence; absence of supportive compendia or FDA approval may result in denial

Combination and Step-therapy Notes

Step	Requirement	Coverage
1	Prescribed in combination with a specified endocrine therapy (an aromatase inhibitor such as anastrozole, exemestane, or letrozole) as initial endocrine-based therapy in postmenopausal women or in men, or prescribed in combination with fulvestrant for disease progression following endocrine therapy.	Coverage is allowed with criteria (authorization may be granted up to 12 months).

Background

Palbociclib (Ibrance) is indicated for use in combination with endocrine therapies for patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. Authorization considerations in this policy reference its use with an aromatase inhibitor or with fulvestrant for recurrent, advanced, or metastatic HR-positive, HER2-negative disease.

Definitions and Key Terms

HR-positive, HER2-negative

DefinitionHormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative tumor status required for the listed breast cancer indications (advanced or metastatic).

ContextSpecifically applies to Ibrance (palbociclib) when used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or in combination with fulvestrant for disease progression following endocrine therapy.

Documentation requirementSubmit HR and HER2 status to initiate prior authorization review where applicable.

ScopeThis biomarker profile is the primary covered breast cancer indication for palbociclib per the policy's coverage criteria.